Aprea Therapeutics
APRE | NASDAQ
$0.45
-$0.05 (-10.18%)
At close: Nov 10, 2026, 4:00 PM ET
-10.18%
(1D)No price chart data available for 1D timeframe.
Rating
36.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #630/1027 (Top 61%)
Key Statistics
Market Data
Market Cap $5.61M
1D Range
0.44 0.51
52W Range
0.44 1.32
Valuation (TTM)
PE -0.64
PB 0.16
EV/EBITDA N/A
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $2.10
Cash Flow
FCF Yield -227.1%
SBC Adj. FCF Yield -234.4%
SBC Impact -3.2%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -109.4% |
-1.8%
Dil EPS 3Y | 5Y 55.9% |
55.0%
FCF 3Y | 5Y 4.0% |
21.5%
Returns
ROA -36.4%
ROE -44.3%
ROIC -43.9%
Financial Health
Net Cash
$37.85M
Current Ratio 9.67
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on mo...
Sector Healthcare
Industry Biotechnology
Employees 8
IPO Date Oct 3, 2019
Website www.aprea.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$2.10
Upside
+366.67%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove APRE